Published • loading... • Updated
Hipra Seeks to Reduce the Development of New Vaccines in Case of Health Emergencies to 100 Days: 'Time Is the Most Valuable'
Summary by laprovincia.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
laprovincia.es+2 Reposted by 2 other sources
'Speedcell', the project coordinated by the Catalan biopharmaceutical company Hipra that seeks to accelerate the development of vaccines and biological drugs in the face of new health emergencies to 100 days, is already one year old. Laura Ferrer, director of R & D in the area of Human Health of biopharmaceuticals based in Girona, takes stock for EL PERIÓDICO of an initiative that seeks to anticipate these threats. "Preparing in calm times is wh…
Coverage Details
Total News Sources3
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
